Neuroimmunology 🧠 🔥 clinician scientist @MGHNeurology, @BWHNeurology. Grad of @harvardneuroMDs & @mcgillmed.
Boston, MA
Joined December 2011
- Tweets1.3K
- Following1.6K
- Followers1.6K
- Likes5.6K
Phil Bilodeau, MD retweeted
What happens after a #MOGAD attack? A new @FrontNeurol review explores relapse prevention, steroid tapering, symptom management & emerging treatments.
TSF funded the paper’s publication fees to support access to research.
📖 Read: doi.org/10.3389/fneur.2026.1…
Phil Bilodeau, MD retweeted
Antibodies against MLC1 found in patients with NMOSD-like disease mediate astrocytopathy in rodent models
science.org/doi/10.1126/scit…
Phil Bilodeau, MD retweeted
Theres an important attending level skill of putting on sterile gloves really slowly. It is highly effective at making trainees succeed at arterial lines.
Exciting work led by Drs Natalia Drosu and Kjetel Bjornevik in @ScienceMagazine (STM): CD4 T cells react to EBV late lytic antigens in MS, and these responses, along with viral shedding, are significantly reduced by B-cell therapy. Anti-viral trial in MS? science.org/doi/10.1126/scit…
Phil Bilodeau, MD retweeted
Happy to share @andreuvilaseca7 et al. observational #MOGAD study of IL-6R blockade across Americas showing low relapse rates similar to high-dose IVIG, supporting this therapeutic mechanism & globally available tocilizumab may expand access worldwide👇jamanetwork.com/journals/jam…
As trainees who work with me know, I’m quite fond of using tocilizumab to treat acute inflammation. Here in @JAMANeuro , we show good outcomes when IL-6 receptors blockers are used as rescue therapy in NMOSD and MOGAD. Time for an acute treatment trial?
jamanetwork.com/journals/jam…
Excited to share our new paper in @GreenJournal N2. We found better effectiveness and safety outcomes with complement inhibitors, inebilizumab and satralizumab, compared with rituximab. neurology.org/doi/10.1212/NX…
Phil Bilodeau, MD retweeted
"We aim to compare the efficacy and safety of rituximab...with recently approved #NMOSD-specific #treatments—eculizumab, inebilizumab, satralizumab—& other common off-label NMOSD treatments—mycophenolate mofetil & azathioprine." doi.org/10.1212/NXI.00000000… @shamik_b @phil_bilodeau
I am very grateful to @PCORI for funding our clinical trial on the comparative effectiveness of immunotherapies in NMOSD. Huge shout-out to our entire team: @TheSumairaFDN, Prof. Friedemann Paul, and Dr. Marcelo Matiello, without whom this would not have been possible.
I make a point of deleting the handedness out of every one-liner…Mostly useless piece of information which only bloats the notes
Absolutely brilliant read from @tompollak about the dangers of attributing everything to inflammation. I would add that we, as a field, cannot even agree on what constitutes pathologic inflammation.
academic.oup.com/brain/artic…
If you treat MOGAD patients, check out our editorial on B-cell depletion in MOGAD!
msard-journal.com/article/S2…
Phil Bilodeau, MD retweeted
Interesting study. Need to be careful though with potentially overinterpreting this and other retrospective observational studies purported to prove the effectiveness of early PLEX. My detailed rapid response to this article is here: jnnp.bmj.com/content/early/2…
Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacks
jnnp.bmj.com/content/early/2… @NeuroVisionLab
Very important paper our lab led by Dr. Natalia Drosu. We identified DR15-restricted epitopes recognized by EBV-specific CD4 T cells. Findings support the use of antiviral therapies/antigen-specific deletion of EBV-targeting CD4 T cells in MS.
tinyurl.com/48vfswkr
ALT D4 T cells restricted to DRB1*15:01 recognize two Epstein–Barr virus glycoproteins capable of intracellular antigen presentation
Phil Bilodeau, MD retweeted
🔍Editor’s Choice Paper
🛎️Welcome to this review "The Impact of Anti-Amyloid Immunotherapies on Stroke Care".
✍️by @phil_bilodeau et al. @MarielKozberg
🔗More details: mdpi.com/2687472
@MediPharma_MDPI @harvardmed
#mdpijcm #Stroke #neurotwitter
How will anti-amyloid immunotherapies and ARIA affect stroke care? @phil_bilodeau, John Dickson, and I review the latest data on ARIA in the context of acute stroke care and secondary stroke prevention here: secure-web.cisco.com/1xmfXF0…
#RTwitter, any straightforward way of incorporating iptw weights into brms when doing a Bayesian analysis?
This! Always keep MOG on your differential for cortical encephalitis and remember it may not be on the autoimmune encephalopathy panel (for Mayo it is not).
1/
A 34 yo M presents with worsening confusion and seizures. He is febrile.
He is intubated and transferred to the NeuroICU.
A #continuumcase about a cause that’s probably low (not) on your DDx.
Great thread! Would also mention tocilizumab as an acute treatment for fulminant ADEM esp if intracranial hypertension. neurology.org/doi/10.1212/NX…
